SOM researchers find popular weight loss drug vastly reduces heart attacks and strokes
A large clinical trial has shown that oral Semaglutide significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and chronic kidney disease.